PubMed-compiled information sheet
This sheet was compiled from PubMed (NIH) abstracts using AI assistance. Every factual claim is cited to a real PubMed article (see the source list). It has not yet been human-reviewed — confirm with a healthcare provider before use.
Compiled from 30 PubMed articles · model: gemma4:31b
Summary
Parietaria (pellitory-of-the-wall) is a genus of Urticaceae weeds whose pollen is a primary cause of allergic reactions in the Mediterranean region [PMID:12660421, PMID:30544607].
Background
Parietaria is a genus of dicotyledonous weeds in the Urticaceae family, including species such as P. officinalis and P. judaica [PMID:12660421, PMID:41079755]. It is widespread in the Mediterranean basin, particularly in southern Italy and coastal Spain [PMID:1485645, PMID:30544607].
Traditional uses
Parietaria judaica is one of the most widely used Arabian traditional medicinal plants, utilized for its ability to treat several infectious diseases and other illnesses [PMID:33415153].
Active compounds
The major allergens identified in P. judaica pollen are Par j 1 and Par j 2, which belong to the nonspecific lipid transfer protein (LTP) family [PMID:12660421, PMID:25284812].
Mechanism of action
Pollen allergens act as multivalent proteins that cross-link IgE antibodies on mast or basophil cells, triggering the secretion of biologic mediators and resulting in allergic symptoms [PMID:10753015].
Clinical evidence
Evidence BAllergic Rhinitis
Local nasal immunotherapy (LNIT) significantly reduced clinical symptoms and drug intake compared to placebo [PMID:12947995].
Evidence AAllergic Rhinitis
Sublingual immunotherapy with monomeric allergoids showed clear improvement in clinical and drug consumption scores [PMID:16752693].
Evidence DPollinosis
Sublingual immunotherapy with specific allergens resulted in marked improvement of sneezing, itching of the eyes, and rhinitis in 12 out of 14 patients [PMID:8940498].
Safety & adverse effects
Adverse reactions to Parietaria vaccines can include severe urticaria [PMID:8940498]. Rare cases of suspected anaphylaxis to P. judaica pollen have been reported [PMID:28710239].
Evidence summary
The evidence is primarily focused on the herb's role as a potent allergen and the efficacy of various immunotherapy protocols (sublingual and nasal) to treat Parietaria-induced allergic rhinitis, with evidence levels ranging from case reports to meta-analyses.
PubMed sources
- 1.PMID: 41079755 (2024) — The genome sequence of pellitory-of-the-wall, Parietaria judaica L. (Urticaceae). · Wellcome open research
- 2.PMID: 12660421 (2003) — The allergens of Parietaria. · International archives of allergy and immunology
- 3.PMID: 16752693 (2006) — Monoid sublingual immunotherapy. · European annals of allergy and clinical immunology
- 4.PMID: 30544607 (2018) — Parietaria Allergy: An Intriguing Challenge for the Allergist. · Medicina (Kaunas, Lithuania)
- 5.PMID: 25284812 (2015) — Multiple IgE recognition on the major allergen of the Parietaria pollen Par j 2. · Molecular immunology
- 6.